ArticleMedicine2026
Analysis of Clavien-Dindo classification and risk factors for complications after transurethral Thulium Laser enucleation of the prostate.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the risk factors for postoperative complications following transurethral thulium laser enucleation of the prostate (ThuLEP) and provide references for reducing the occurrence of postoperative complications. A retrospective analysis was conducted on 103 patients with benign prostate hyperplasia who underwent ThuLEP from September 2020 to August 2022. Among them, 95 patients had complete clinical and follow-up data. Clinical data and follow-up information of the patients were collected. Univariate and multivariate logistic regression analyses were performed to identify the influencing factors of postoperative complications following ThuLEP. The incidence of postoperative complications following ThuLEP was 11.58% (11/95), among which the rates of Grade I, II, and III complications were 3.16% (3/95), 3.16% (3/95), and 5.29% (5/95), respectively. The prostate volume after ThuLEP was 96.11 ± 43.38 ml in the uncomplication group and 139.71 ± 96.41 ml in the complication group, and there was a statistically significant difference between the 2 groups (P = .02). The prostate mass after ThuLEP was 46.99 ± 22.14 ml in the uncomplication group and 70.25 ± 41.37 ml in the complication group, and there was a statistically significant difference between the 2 groups (P = .01). The postoperative catheter removal time after ThuLEP was 3 ± 1.04 days in the uncomplication group and 2 ± 1.49 days in the complication group, and there was a statistically significant difference between the 2 groups (P = .02).Univariate and multivariate logistic regression analyses revealed that the postoperative catheter removal time (P = .046) was an independent risk factor for Grade II-III complications after ThuLEP. Prostate volume and prostate mass are influencing factors for postoperative complications following ThuLEP. Postoperative catheter removal time is an independent risk factor for postoperative complications following ThuLEP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.